|Articles|February 14, 1996

Regulatory signs look good for AMI agent

Advanced Magnetics passed an important milestone earlier thismonth when the Food and Drug Administration issued a letter statingthat the new drug application for the company's Feridex MRI contrastagent is approvable. Advanced Magnetics, of Cambridge, MA, saidthat it is working with the FDA on final labeling for the agentas well as to resolve several questions relating to the NDA, whichwas filed in February 1994.

Feridex is an intravenous contrast agent designed to enhanceprimary and metastatic tumors in the liver on MRI scans. AdvancedMagnetics has licensed the agent to Berlex Laboratories in theU.S. and Canada (SCAN 2/15/95). Feridex is sold in Europe by Guerbetunder the trade name Endorem.

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Related to this article

October 6th, 2026

Interventional Radiology in Focus: A Closer Look at Prostatic Artery Embolization for Benign Prostatic Hyperplasia

In the latest episode of his “Interventional Radiology in Focus” series, Mina Makary, MD, discusses the utility of prostatic artery embolization for treating benign prostatic hyperplasia, key imaging considerations and pertinent technique pearls to help facilitate optimal outcomes.

October 6th, 2026

FDA Clears MRI-Based AI Software for Body Composition Analysis

The AI-powered SwiftSight Body Composition software reportedly provides automated quantification of muscle and adipose tissue after a brief MRI scan.

October 5th, 2026

The Reading Room Podcast: Current Perspectives, Challenges and Possibilities with AI in Breast Imaging, Part 2

In the second of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD discuss how to handle disagreements with adjunctive AI in breast imaging, whether to include AI assessments in PACS, and whether patients should pay for the use of adjunctive AI.

October 5th, 2026

Security: A Way to Be Safe and Unproductive in Radiology

Has the barrage of passwords, PINs and authenticator apps gone around the bend to a point where it hampers efficiency and productivity?

October 4th, 2026

Diagnostic Imaging's Weekly Scan: September 27 — October 3

Catch up on the top radiology content of the past week.

October 3rd, 2026

Emerging Research Insights and New Advances in Neuroradiology

Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.

October 2nd, 2026

MRI, CT or Ultrasound: Which Modality Offers the Most Utility for Imaging of Pancreatic Cancer?

Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.

October 1st, 2026

Current Perspectives on Integrating AI into Radiology

In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.